RT Journal Article
SR Electronic
T1 SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of MS patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.18.20248500
DO 10.1101/2020.12.18.20248500
A1 Ostendorf, Lennard
A1 Dittert, Philipp
A1 Biesen, Robert
A1 Duchow, Ankelien
A1 Stiglbauer, Victoria
A1 Ruprecht, Klemens
A1 Seelow, Dominik
A1 Niesner, Raluca A.
A1 Hauser, Anja E.
A1 Paul, Friedemann
A1 Radbruch, Helena
YR 2020
UL http://medrxiv.org/content/early/2020/12/22/2020.12.18.20248500.abstract
AB Objective We aimed to evaluate SIGLEC1 (CD169) as a biomarker in Multiple Sclerosis (MS) and Neuromyelitis optica spectrum disorder (NMOSD) and to evaluate the specificity of SIGLEC1+ myeloid cells for demyelinating diseasesMethods We performed flow cytometry-based measurements of SIGLEC1 expression on monocytes in 86 MS patients, 41 NMOSD patients and 31 healthy controls. Additionally, we histologically evaluated the presence of SIGLEC1+ myeloid cells in acute and chronic MS brain lesions as well as other neurological diseases.Results We found elevated SIGLEC1 expression in 16/86 (18.6%) MS patients and 4/41 (9.8%) NMOSD patients. Almost all MS patients with high SIGLEC1 levels received exogenous interferon beta as an immunomodulatory treatment and only a small fraction of MS patients without interferon treatment had increased SIGLEC1 expression. SIGLEC1+ myeloid cells were abundantly present in active MS lesions as well as in a range of acute infectious and malignant diseases of the central nervous system, but not chronic MS lesions.Conclusion In our cohort, SIGLEC1 expression on monocytes was – apart from those patients receiving interferon treatment – not significantly increased in patients with MS and NMOSD, nor were levels associated with more severe disease. The presence of SIGLEC1+ myeloid cells in brain lesions could be used to investigate the activity in an inflammatory CNS lesion.Competing Interest StatementThe authors have declared no competing interest.Funding StatementLO was supported by the BIH-MD Promotionsstipendium of the Charité - Universitätsmedizin Berlin and the Berlin Institute of Health and was a member of the Leibniz Graduate School for Chronic Inflammation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:These studies were approved by the ethics committee of the Charité - Universitätsmedizin Berlin (references: EA1/163/12, EA1/041/14, EA1/107/13) and informed consent was obtained from all participants in the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll datasets used and analysed during the current study are available from the corresponding authors on request.